The development of any cell and gene therapy must overcome multiple challenges to avoid failed treatments.
There is a lack of clinically validated tools available to researchers to aid in the monitoring cellular status in a reliable way, and hence contributing to the decision-making process during therapy development.
Cell characterization, vector monitoring and quality assurance through a comprehensive panel of multiple biomarkers can help you address these problems while saving time and money.
CELL THERAPIES
Cell monitoring and characterization:
- Cells with short telomeres are closer to senescence. Ensure an optimal telomere length to improve in vivo survival.
- Verify telomeres are long enough in order to protect plasticity in stem cell-like cells.
- Stain and measure specific cells types. Ideal for xenografts, focus on different cell populations, origins, etc.
- Determine cell infiltration and specific cell-type markers (mTOR, PD1-PDL1, ILs…)
Donor/ sample selection:
- Ensure that you start your cell expansions/processing with the best samples.
Biosafety:
- Hyperactivated telomerase activity is a hallmark of cancer. Monitor telomerase activity to discard potential tumorigenicity after cellular expansions or modifications.
GENE THERAPIES
Cells are widely used in gene therapy for multiple purposes. Evaluate cellular status after introducing modifications through telomere length and other important markers.
Monitor everything around the expression of your gene therapy:
- Confirm and quantify the expression of the gene editing system on your target population.
- Compare and select the vector with the most optimal response.
- Asses viral tropism and the successful delivery of the desired gene.
- Distinguish transgene from vector genome ensuring the transfer of the desired gene.
APPLIED EXAMPLES
Select the best donor:
Monitor your expansion and how far are cells from senescence:
Telomerase activity monitoring:
Telomere length measurement
Xenografts
